biostudies-literatureUnknown7(2)Barca-Hernando M<h4>Background</h4>Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.<h4>Objectives</h4>To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).<h4>Methods</h4>We performed a retrospective study on consecutive patients with CAT recruited between 2008 and 2019. The primary and secondary outcomes were recurrent VTE at 6 and 12 months, respectively. Sensitivity analyses were conducted to investigate the possible heterogeneity of these effects.<h4>Results</h4>A total of 311 patients were included, among whom 33.4% hResearch and practice in thrombosis and haemostasis100115https://www.ebi.ac.uk/biostudies/studies/S-EPMC10099299biostudies-literatureRisk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.PMC10099299Carrier MBarca-Hernando MGarcia-Garcia VElias-Hernandez TOtero-Candelera RMarin-Romero SJara-Palomares LLopez-Ruz SfalseRisk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy.<h4>Background</h4>Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.<h4>Objectives</h4>To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).<h4>Methods</h4>We performed a retrospective study on consecutive patients with CAT recruited between 2008 and 2019. The primary and secondary outcomes were recurrent VTE at 6 and 12 months, respectively. Sensitivity analyses were conducted to investigate the possible heterogeneity of these effects.<h4>Results</h4>A total of 311 patients were included, among whom 33.4% h2023-01-01T00:00:00Z2023 Feb2025-04-04T07:11:19.518Z2025-04-04T07:11:19.518ZS-EPMC100992993706376110.1016/j.rpth.2023.100115